Home > Name List By other > (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5, 5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16, 17-decahydrocyclop...

CAS No 129453-61-8 , (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,
5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,
17-decahydrocyclopenta[a]phenanthrene-3,17-diol

  • Name: (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,
    5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,
    17-decahydrocyclopenta[a]phenanthrene-3,17-diol
  • Synonyms: Ici 182780;Faslodex; Faslodex (TN); ICI 182,780; ICI-182780;(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,
    5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,
    17-decahydrocyclopenta[a]phenanthrene-3,17-diol; S1191_Selleck; ZM 182780; 129453-61-8; Fulvestrant [USAN];
  • CAS Registry Number:
  • Density: 1.201 g/cm3
  • Refractive index: 1.521
  • Molecular Weight: 606.770796
  • InchiKey: VWUXBMIQPBEWFH-WCCTWKNTSA-N
  • InChI: InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)
    27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,
    36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,
    30+,41?/m1/s1
  • Molecular Formula: C32H47F5O3S
  • Molecular Structure:CAS No:129453-61-8 (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,<br />5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,<br />17-decahydrocyclopenta[a]phenanthrene-3,17-diol

Related products

Search by region :

Select to

129453-61-8 Fulvestrant

  • China sunpharmachem null
  • Tel: sales@sunpharmachem.com
  • Address: shanghai china null,shanghaiChina
Contact Supplier

129453-61-8 Fulvestrant

Contact Supplier

129453-61-8 Fulvestrant

  • China Hangzhou Hetd Pharm&Chem Co.,Ltd. null
  • Tel: 86-571-81958080
  • Fax: 86-571-81958068
  • Address: No. 8, Xiyuan Yi Road, Xihu Industrial Park, Hangzhou, China null,nullChina
Contact Supplier

129453-61-8 Fulvestrant

Contact Supplier

129453-61-8 Fulvestrant

Contact Supplier

129453-61-8 Fulvestrant

  • China Ningbo Ubest Import&Export Co.,Ltd [Importer/Exporter]
  • Tel: +86-575-86036626 +86-574-87972156
  • Fax: +86-575-86041458
  • Address: 10A-3,Block A, Jiayi Square, Xinchang County, Zhejiang, China Xinchang,ZhejiangChina
Contact Supplier

129453-61-8 Fulvestrant

  • China sklichem lab [Manufacturers]
  • Tel: +86-13764363574
  • Fax: +86-13764363574
  • Address: No.21, Tangxi Road,Suzhou New District,215151,China null,JiangsuChina
Contact Supplier

129453-61-8 Fulvestrant

  • China Loyal Chemistry Technology [Manufacturer, Trading Company, Government ministry/Bureau/Commission]
  • Tel: 86-21-37285211
  • Address: null null,nullChina
Contact Supplier

129453-61-8 Fulvestrant

  • Fulvestrant, 99%
  • China Sunshine Pharmaceutical Group [Manufacturer]
  • Tel: 86 10 63813532
  • Fax: 86 10 63854028
  • Address: B,Yuntongxing Business Buiding, No.57 East Street, Fengtai Zone, Beijing,China100071 BeijingCHINA Beijing,nullChina
Contact Supplier

129453-61-8 Fulvestrant

Contact Supplier

Select to

13/15
Previous 6 7 8 9 10 11 12 13 14 15 Next
References of (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,
5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,
17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Title: Fulvestrant
CAS Registry Number: 129453-61-8
CAS Name: (7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol
Manufacturers' Codes: ICI-182780
Trademarks: Faslodex (AstraZeneca)
Molecular Formula: C32H47F5O3S
Molecular Weight: 606.77
Percent Composition: C 63.34%, H 7.81%, F 15.66%, O 7.91%, S 5.28%
Literature References: Novel steroidal estrogen antagonist reported to lack any partial agonist activity. Prepn: J. Bowler, B. S. Tait, EP 138504; eidem, US 4659516 (1985, 1987 both to ICI). Pharmacology: A. E. Wakeling et al., Cancer Res. 51, 3867 (1991). Clinical pharmacokinetics: A. Howell et al., Br. J. Cancer 74, 300 (1996). Clinical evaluation in breast cancer vs tamoxifen: J. F. Robertson et al., Cancer Res. 61, 6739 (2001). Clinical trial in advanced breast cancer: J. N. Ingle et al., J. Clin. Oncol. 24, 1052 (2006). Review of mechanism of action and clinical evaluation: idem, Br. J. Cancer 85, Suppl. 2, 11-14 (2001); A. Howell, Crit. Rev. Oncol. Hematol. 57, 265-273 (2006); of tolerability profile: I. Vergote, P. Abram, Ann. Oncol. 17, 200-204 (2006).
Therap-Cat: Antineoplastic (hormonal).
Keywords: Antineoplastic (Hormonal); Antiestrogens.